No Data
Vera Therapeutics | 10-Q: Quarterly report
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Vera Therapeutics Is Maintained at Strong Buy by Raymond James
Vera Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 66.34% Raymond James $57 → $68 Maintains Strong Buy 04/05/2024 36.99% Guggenheim → $56 Reiterat
Express News | Vera Therapeutics Inc : Raymond James Raises Target Price to $68 From $57
Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating
Vera Therapeutics (VERA) has an average rating of buy and price targets ranging from $25 to $107, according to analysts polled by Capital IQ. Price: 41.55, Change: -0.78, Percent Change: -1.84
Express News | UPDATE: Vera Therapeutics Q1 EPS $(0.56) Up From $(0.80) YoY